Abstract
5514Background: PARP inhibitors (PARPi) are approved as active treatment only for pts with BRCA mutations. The PARPi niraparib demonstrated increased PFS vs placebo in the maintenance setting of pl...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have